Eifel P, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–89. https://doi.org/10.1093/jnci/93.13.979.

Article  CAS  PubMed  Google Scholar 

Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135–55. https://doi.org/10.2174/1574884711308020006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.

Article  Google Scholar 

Davies C, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. https://doi.org/10.1016/s0140-6736(11)60993-8.

Article  CAS  PubMed  Google Scholar 

Gray R, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. 2013. https://doi.org/10.1200/jco.2013.31.18_suppl.5.

Article  PubMed  PubMed Central  Google Scholar 

Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16. https://doi.org/10.1016/s0140-6736(12)61963-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali S, et al. Molecular mechanisms and mode of tamoxifen resistance in breast cancer. Bioinformation. 2016;12:135–9. https://doi.org/10.6026/97320630012135.

Article  PubMed  PubMed Central  Google Scholar 

Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18. https://doi.org/10.1056/nejm199811263392207.

Article  CAS  PubMed  Google Scholar 

O’Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 2002;3:207–14. https://doi.org/10.1016/s1470-2045(02)00711-8.

Article  CAS  PubMed  Google Scholar 

Powles TJ, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704–8. https://doi.org/10.1093/jnci/90.9.704.

Article  CAS  PubMed  Google Scholar 

Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84. https://doi.org/10.1200/jco.1996.14.1.78.

Article  CAS  PubMed  Google Scholar 

van Weelden WJ, Massuger L, Pijnenborg JMA, Romano A. Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol. 2019;9:359. https://doi.org/10.3389/fonc.2019.00359.

Article  PubMed  PubMed Central  Google Scholar 

Kristensen B, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992–7. https://doi.org/10.1200/jco.1994.12.5.992.

Article  CAS  PubMed  Google Scholar 

Saarto T, et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75:602–5. https://doi.org/10.1038/bjc.1997.105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158–62. https://doi.org/10.1210/jcem.83.4.4688.

Article  CAS  PubMed  Google Scholar 

Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 1993;22:87–94. https://doi.org/10.1016/s0169-6009(08)80220-6.

Article  CAS  PubMed  Google Scholar 

Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22:3694–9. https://doi.org/10.1200/jco.2004.08.148.

Article  PubMed  Google Scholar 

Kim M, et al. Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients. Breast Cancer Res Treat. 2020;180:657–63. https://doi.org/10.1007/s10549-020-05566-w.

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535. https://doi.org/10.1136/bmj.b2535.

Article  PubMed  PubMed Central  Google Scholar 

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117.

Article  PubMed  PubMed Central  Google Scholar 

Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.

Article  Google Scholar 

Love RR, et al. Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer. Cancer. 2013;119:3746–52. https://doi.org/10.1002/cncr.28302.

Article  CAS  PubMed  Google Scholar 

Hojan K, Milecki P, Molińska-Glura M, Roszak A, Leszczyński P. Effect of physical activity on bone strength and body composition in breast cancer premenopausal women during endocrine therapy. Eur J Phys Rehabil Med. 2013;49:331–9.

CAS  PubMed  Google Scholar 

Nuzzo F, et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012;23:2027–33. https://doi.org/10.1093/annonc/mdr600.

Article  CAS  PubMed  Google Scholar 

Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96:1336–43. https://doi.org/10.1210/jc.2010-2582.

Article  CAS  PubMed  Google Scholar 

Henry NL, et al. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer. 2010;102:294–300. https://doi.org/10.1038/sj.bjc.6605460.

Article  CAS  PubMed  Google Scholar 

Gnant MF, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–8. https://doi.org/10.1200/jco.2005.02.7102.

Article  CAS  PubMed  Google Scholar 

Lee J, et al. Effect of tamoxifen on the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors: a nationwide study. Front Oncol. 2020;10:366. https://doi.org/10.3389/fonc.2020.00366.

Article  PubMed  PubMed Central  Google Scholar 

Stumpf U, Kostev K, Kyvernitakis J, Böcker W, Hadji P. Incidence of fractures in young women with breast cancer—a retrospective cohort study. J Bone Oncol. 2019;18:100254.